US 2021/0230251 A1 · UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER

Abstract

A nucleic acid molecule comprising a nucleotide sequence encoding an inhibitory chimeric antigen receptor (i CAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the i CAR comprises an extracellular domain that specifically binds to a single allelic variant of a polymorphic cell surface epitope absent from mammalian tumor cells due to loss of heterozygosity (LOH) but present at least on all cells of related mammalian normal tissue; and an intracellular domain comprising at least one signal transduction element that inhibits an effector immune cell is provided. Vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.

Claims15

Dependent claims

A nucleic acid molecule encoding an inhibitory chimeric antigen receptor (iCAR) construct, the iCAR construct comprising:

i) an extracellular domain comprising a single chain variable fragment (ScFv) that specifically binds to a cell surface antigen selected from the group consisting of HLA-A2, CD19, CD20, or mesothelin (MSLN), wherein the cell surface antigen is expressed on the surface of tumor cells of a subject;
ii) an intracellular domain comprising a signal transduction element, wherein the signal transduction element is homologous to a signal transduction element of LIR1;
and
iii) a hinge domain and a transmembrane domain linking the extracellular domain to the intracellular domain.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

17/175,565Filed 12 Feb 2021

Priority

28 Sep 2016

Published

29 Jul 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification39 codes

C07K 14/70539
Immunoglobulin superfamily: mHC-molecules, e.g. HLA-molecules
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/4211
Immunoglobulin superfamily: cd19 or b4

Universal platform for car therapy targeting a novel antigenic signature of cancer

Life of this patent

Universal platform for car therapy targeting a novel antigenic signature of cancer

Life of this patent

Abstract

Claims15